D&D Pharmatech is showing a strong rebound on the 10th, recording double-digit gains during intraday trading.

The company's stock price had been significantly shaken by the recent news of the discontinuation of its oral obesity drug candidate. As a result, the market is increasingly perceiving the decline as excessive, while attention is shifting back to the company's other core pipeline assets.

As of 2:12 p.m. on the 10th, D&D Pharmatech is trading at 65,100 won, up 7,600 won (13.22%) from the previous trading day. Intraday trading volume has exceeded 1.65 million shares. During the same session, the stock rose to as high as 66,000 won, with the gain exceeding 14%.

Looking at the recent stock price trend, volatility has been considerable. D&D Pharmatech plunged 18.06% on the 5th, closing at 53,100 won, before rebounding for two consecutive days to 55,700 won on the 6th and 57,500 won on the 7th. With the gains expanding again today, the stock price that had sharply fallen in the short term is recovering a significant portion of its losses.

D&D Pharmatech is a biotech company that has been developing new drugs for obesity and metabolic diseases based on GLP-1 peptide technology.

However, with the stock price rebounding rapidly, it is necessary to verify clinical results of individual pipelines and official company announcements, independent of short-term price movements. In the stock market, following a sharp surge, the upward trend rarely continues uninterrupted; instead, volatility often expands as buying pressure collides with profit-taking volumes. For D&D Pharmateck as well, double-digit gains and declines have alternated over the past few days, making it difficult to judge the stock's direction based solely on a single day's gains.

[This article is provided as reference material for investment decisions and does not recommend the purchase or sale of any specific stock. Stock investments may result in principal loss, and the final judgment and responsibility for investments lie with the investor. This article was written with AI assistance.]